drugset / Trial / NCT06702566
The Effect of Serum Ferritin in irAE
Non-randomizedSequentialOpen-labelDiagnostic
Summary
This is a prospective clinical study to clarify serum ferritin as a biomarker for the diagnosis, differential diagnosis and prognosis of immune-related adverse event(irAE).
Timeline
- Start
- 2024-07-04
- Primary completion
- 2026-07-16
- Completion
- 2027-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Adebrelimab | Monoclonal antibody | — | — |
| Background | Atezolizumab | Monoclonal antibody | — | — |
| Background | Camrelizumab | Monoclonal antibody | — | — |
| Background | Durvalumab | Monoclonal antibody | — | — |
| Background | Envafolimab | Monoclonal antibody | — | — |
| Background | Nivolumab | Monoclonal antibody | — | — |
| Background | Pembrolizumab | Monoclonal antibody | — | — |
| Background | Serplulimab | Monoclonal antibody | — | — |
| Background | Sintilimab | Monoclonal antibody | — | — |
| Background | Tislelizumab | Monoclonal antibody | — | — |
| Background | Triplimab | Unknown | — | — |